Skip to content
Companies

Iyuda Therapeutics

Off-the-shelf donor cell therapy for cancer

Raised to date

$600K

of $600K offered across 1 Form D filing

Investors
2
Last filed
Apr 6, 2026

About

Iyuda Therapeutics is a Maryland biotechnology company developing allogeneic cell therapies for cancer and other immune-mediated diseases, built on immunology work from Johns Hopkins. Its published patent portfolio, co-assigned with The Johns Hopkins University, covers non-engrafting, CD8-depleted allogeneic donor lymphocyte infusions designed to deliver anti-tumor activity from a mismatched donor without causing graft-versus-host disease. Related filings cover leukocyte compositions enriched for CD4+ Th1 cells and immune cells modified to suppress kinases such as BTK and ITK for adoptive cell therapy. The company is pre-commercial; its public web presence is a single placeholder page.

Uses deliberately non-engrafting, CD8-depleted donor lymphocytes from an HLA-mismatched donor, aiming to separate the graft-versus-tumor effect from the graft-versus-host toxicity that limits conventional donor lymphocyte infusion.

Funding

  • EquityFiled Apr 6, 2026Form D
    $600K/ $600K

Product

Non-engrafting CD8-depleted allogeneic donor lymphocyte infusion

Adoptive cell therapy

An off-the-shelf allogeneic cell therapy built from isolated leukocytes taken from an HLA-mismatched donor and depleted of CD8+ T cells, formulated so the cells do not engraft in the recipient. The approach is the subject of the company's lead patent family, filed in 2022 and published in the US, EP, WO and JP.

  • Donor leukocytes mismatched to the recipient at one or more HLA loci
  • CD8+ T cell depletion to reduce toxicity
  • Non-engrafting design so the infused cells clear rather than establish chimerism

Built for

Patients with hematologic malignancies and other cancers treated at transplant and cellular therapy centers, reached through hematologist-oncologists; near-term counterparties are clinical partners and investors including Johns Hopkins Technology Ventures.

People on file